
















have	been	vastly	overlooked,	with	 little	 research	 in	 the	area.	Therefore,	 in	 this	 study	we	explored	 this	 further;	by	assessing	 the	potential	 of	P2YRs	 to	mediate	 inhibition	of	 cytokine-mediated	 JNK	signalling	and	 related















Early	 studies	 recognised	 that	 ATP	 and	 adenosine	 were	 particularly	 important	 in	 the	 mechanisms	 underlying	 local	 control	 of	 vessel	 tone	 [5],	 as	 well	 as	 cell	 migration,	 differentiation	 and	 death	 during	 angiogenesis,
atherosclerosis,	and	restenosis	following	angioplasty		[6,	7].	Extracellular	ATP	has	also	been	shown	to	drive	systemic	 inflammation,	and	 tissue	damage	 in	murine	models	of	LPS-induced	 inflammation	 [8].	More	 recently	purinergic
signalling	has	been	shown	to	play	a	role	in	inflammation	and	cancer,	where	activation	of	P2Y11	inhibits	the	migration	of	tumour	derived	endothelial	cells	via	cAMP	signalling	[9].
The	cellular	actions	of	P2Y1,	P2Y2,	and	P2Y11	have	been	shown	to	be	mediated	through	the	activation	of	a	number	of	key	signalling	pathways.	These	include	the	extracellular	regulated	protein	kinases,	namely	ERK	[1]	and	the
stress-activated	protein	kinases,	p38	MAP	kinase,	and	c-Jun	N-terminal	kinase	 (JNK)	 [10,	11],	however,	 the	exact	mechanisms	 involved	 in	P2YR	activation	of	 these	pathways	are	still	not	 fully	understood.	 In	Human	umbilical	vein
endothelial	cells	(HUVECs),	activation	of	P2Y1	leads	to	both	p38	MAPK	and	JNK	phosphorylation	[11].	Of	the	three	subtypes	described	so	far,	P2Y11	is	the	most	abundantly	expressed	in	HUVECs	[3]	and	its	activation	leads	to	both	IP3
and	cAMP	accumulation,	demonstrating	its	interaction	with	both	Gαq/11	and	GαS	[12,	13].


























To	measure	 JNK	activity,	cells	were	stimulated	as	appropriate	and	 the	reaction	 terminated	by	rapid	aspiration	and	 the	cell	monolayer	washed	with	 ice-cold	PBS.	The	cells	were	solubilised	 in	20 mM	HEPES	buffer,	pH 7.7,
containing	50 mM	NaCl,	0.1 mM	EDTA,	0.1 mM	Na3VO4,	0.1 mM	PMSF,	10	μg/ml	aprotinin,	10	μg/ml	leupeptin,	and	1%	(w/v)	Triton	X-100.	Lysates	were	clarified	by	centrifugation	for	5 min	at	13,000 rpm	and	equal	amounts	of	protein
were	incubated	with	20 μg	of	GST-c-Jun-(5–89)	 immobilized	on	glutathione-Sepharose	at	4 °C	for	3 	hrh.	Beads	were	 then	washed	 three	 times	 in	 solubilisation	buffer	and	 twice	 in	25 mM	HEPES	buffer,	pH 7.6,	containing	20 mM	 β-
glycerophosphate,	0.1 mM	NaV3O4,	2 mM	dithiothreitol.	Precipitates	were	then	incubated	with	the	same	buffer	containing	25	μM/1.85	x	 × 1010 Bq	of	ATP/	[γ










































human	 coronary	 artery	 endothelial	 cells	 and	 similar	 to	 the	 HUVECs	 noted	 a	 concentration	 dependent	 inhibition	 of	 IL-1β	 -	 mediated	 JNK	 activity	 by	 ATP.	 Using	 100	 μM	 ATP	 for	 30 	minutesmin	 pre-treatment	 we	 demonstrated




















In	order	 to	 further	confirm	 the	actions	of	ATP	 in	mediating	 JNK	 inhibition	via	 the	P2Y11	 receptor,	we	 investigated	 further	 the	signalling	mechanisms	 involved.	The	P2Y11	 receptor	 couples	 to	Gαq/11	 to	mediate	downstream
signalling	events;	 therefore	we	examined	 the	 role	of	Gαq/11	 as	 shown	 in	Figure.	4	 panel	C.	 Pre-incubation	 of	HUVECs	with	 the	Gαq/11	 inhibitor	 YM254890	 partially	 reversed	 the	 inhibition	 by	ATP	 of	 IL-1β-induced	 JNK	 activity	 and
phosphorylation	at	30	and	100 nM	YM	by	approximately	45%.
3.5.3.5	ATP-mediated	inhibition	of	cytokine-stimulated	JNK	activation	-	specificity	of	P2Y11














































































































This	 study	 develops	 further	 the	 initial	 phenomena	 uncovered,	 showing	 a	 role	 for	GPCRs	 in	modulating	 pro-inflammatory	 cytokine	 signalling.	 This	 also	 starts	 to	 reveal	 the	 functions	 of	 the	 P2Y11	 receptor	which	 has	 been
historically	difficult	to	research	and	characterise	fully		due	to	a	lack	of	murine	models,	effective	antibody	reagents	to	aid	detection	and	functional	methods	[27].	Taken	together	these	results	highlight	the	importance	of	the	purinergic
receptors,	in	particular	P2Y11,	in	mediating	a	protective	role	against	cytokine	induced	stress-activated	signalling	in	the	endothelium.
Indeed	the	potential	for	GPCRs	to	mediate	inhibition	of	cytokine	driven	JNK	signalling	has	a	number	of	 implications.		It	could	be	envisaged	that	ATP	release	mediated	for	example	by	endothelial	distention	or	stretch	could
dampen	down	inflammation	thus	limiting	the	potential	for	initiation	of	plaque	formation	[55].	Thus,	developing	agonists	which	could	activate	endothelial	cell	GPCRs	or	directly	activate	either	Gαq/11	or	Gαs	may	be	of	clinical	potential	in
the	context	of	inflammatory-based	conditions.
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